Filing Flows › BioNexus Gene Lab (BGLC) › Q3 2025
BioNexus Gene Lab (BGLC) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 14, 2025
BioNexus Gene Lab (BGLC) reported revenue of $2.5M for the third quarter 2025 (Q3 2025), -3% from a year earlier and +13% from the quarter before. Operating margin was -27.6%, net loss $709K (27.9% of revenue).
BioNexus Gene Lab, Q3 2025: revenue $2.5M (-3% year over year), operating margin -27.6%, net loss $709K, operating cash flow −$1.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.5M | +13% | -3% |
| Operating profit | −$703K | — | — |
| Net earnings | −$709K | — | — |
| Operating cash flow | −$1.2M | — | — |
What changed
Revenue was $2.5M in Q3 2025, down 3% year over year and up 13% from the previous quarter.
Gross margin was 14.8%, up 2.4 points from a year earlier. Operating costs exceeded revenue by $703K, an operating margin of -27.6%. Operating expenses fell 35% while revenue fell 3%. The quarter ended with a net loss of $709K, wider than the previous quarter's $616K loss.
Operating cash flow was −$1.2M. Non-cash charges added back $29K of depreciation. Working capital and other items used $557K. Capital expenditures of $5K exceeded it, leaving free cash flow of −$1.2M.
Questions
What was BioNexus Gene Lab's revenue in the third quarter 2025?
BioNexus Gene Lab (BGLC) reported revenue of $2.5M for the third quarter 2025 (Q3 2025), -3% from a year earlier and +13% from the quarter before.
Was BioNexus Gene Lab profitable in the third quarter 2025?
Operating loss was $703K (-27.6% of revenue) and net loss $709K.
Source: BioNexus Gene Lab 10-Q on SEC EDGAR.